ArticlePsychiatry and clinical neurosciences2026
Association between initial 30-day cumulative clozapine dose and risk of agranulocytosis: A nationwide register-based cohort study.
Article in Psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimizing Clozapine Monitoring in Older Adults: A Proposal for Ethnicity- and Sex-Informed Monitoring in Japanese Geriatric Patients.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsClozapine-induced agranulocytosis (CIA) is traditionally considered an idiosyncratic, dose-independent reaction. However, emerging evidence suggests that clozapine-related inflammatory events may exhibit dose-dependent characteristics, leading us to hypothesize that CIA risk may similarly relate to early cumulative exposure.
methodsUsing Japan's nationwide Clozaril Patient Monitoring Service database (2009-2024), the 30-day cumulative dose following initiation was calculated for all treated patients. Participants were stratified into quartiles (Q1-Q4). CIA was defined as two consecutive absolute neutrophil counts <500/mm
resultsAmong 18,189 patients (mean age 42.9 [SD 12.7]; 46.4% female), 138 (0.76%) developed CIA, with no cases occurring within the first 30 days. The incidence rates of CIA in Q1, Q2, Q3, and Q4 were 0.44%, 0.66%, 0.74%, and 1.20%, respectively. Compared with Q1, hazard ratios (HRs) over 180 days were 1.78 (95% confidence interval [CI] 0.96-3.30; P = 0.0659), 2.01 (95% CI 1.10-3.66; P = 0.0233), and 3.07 (95% CI 1.74-5.42; P < 0.001) for Q2, Q3, and Q4, respectively. Male sex and age >40 years were identified as independent risk factors. E-values for Q4 HR were 5.59 (point estimate) and 2.88 (95% CI), indicating high robustness against unmeasured confounders such as co-medications.
conclusionsHigher early cumulative clozapine exposure was associated with increased CIA risk. These findings suggest that early exposure may serve as a clinically relevant marker of CIA risk, although causal inference is limited and further research is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.